Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome | Zendy

Marie-Louise Koepke | Zendy; M. Weber | Zendy; Eckhard Schulze-Lohoff | Zendy; Bogdan Beirowski | Zendy; Stephan Segerer | Zendy; Oliver Groß | Zendy

Open Access

Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome

Author(s) -

Marie-Louise Koepke,

M. Weber,

Eckhard Schulze-Lohoff,

Bogdan Beirowski,

Stephan Segerer,

Oliver Groß

Publication year - 2007

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfl810

Subject(s) - alport syndrome , cerivastatin , medicine , hmg coa reductase , fibrosis , reductase , kidney , hydroxymethylglutaryl coa reductase , pharmacology , endocrinology , glomerulonephritis , enzyme , cholesterol , biology , biochemistry , pravastatin

Alport syndrome is caused by mutations in genes encoding for the alpha3, alpha4 or alpha5 chain of type IV collagen leading to excessive production of fibrotic tissue and end-stage renal failure. HMG-CoA-reductase-inhibitors exhibit pleiotropic effects by which they modulate the production of connective tissue. The aim of this study was to examine the anti-fibrotic effect of the HMG-CoA-reductase-inhibitor, cerivastatin, in COL4A3 knockout mice, an animal model of Alport syndrome with progressive renal fibrosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research